NasdaqCM:VKTXBiotechs
A Look At Viking Therapeutics (VKTX) Valuation As VANQUISH 2 Reaches Full Phase 3 Enrollment
Viking Therapeutics (VKTX) is back in focus after the company reported full patient enrollment in VANQUISH-2, its Phase 3 trial of the obesity and type 2 diabetes candidate VK2735.
See our latest analysis for Viking Therapeutics.
At a share price of US$33.70, Viking’s short term performance has been mixed, with a 6.48% 90 day share price return and a much stronger 45.89% 1 year total shareholder return, suggesting momentum has been building around VK2735 progress.
If this obesity readout has...